

REMARKS

Claims 52-57, 59-63, and 65-69 are pending. Claims 54, 55, 57-62 and 64-66 were objected to, but were not rejected and thus are otherwise in condition for allowance.

Sequence identifiers have been added to the claims. Claim 52 has been amended to include the limitations of Claim 58 and Claim 63 (oligonucleotide) has been amended to include the limitations of Claim 64. New Claim 67 finds support in page 7, line 28, of the specification. Claim 69 finds support in the original claims and on pages 1, 6 and 7 of the specification. Accordingly, the Applicants do not believe that any new matter has been introduced.

Rejection—35 U.S.C. §102


Claims 52, 53, 56 and 63 were rejected under 35 U.S.C. 102(e) as being anticipated by Creasy et al., U.S. Patent No. 6,165,766. This rejection is moot in view of the amendment of independent Claims 52 and 63. Creasy does not disclose a stabilized nucleotide, nor an oligonucleotide consisting of 20-100 nucleotides or base pairs. Moreover, Creasy is generally directed to polynucleotides encoding human protein kinases HYAK3 and does not disclose or suggest an amount of an oligonucleotide comprising AACGTTAT sufficient to exert an antitumor effect. Accordingly, this rejection may now be withdrawn.

Conclusion

In view of the above remarks, the Applicants respectfully submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Thomas M. Cunningham, Ph.D.  
Attorney of Record  
Registration No. 45,394

Customer Number

**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)